Remove Negotiation Remove Pharmaceutical Remove Sale
article thumbnail

E200: Buying or Selling a Small Business? Get the Insider Tips You Need to Secure Your Deal

How2Exit

With a career spanning over a decade, Patrick has become an industry-agnostic specialist, facilitating financial diligence, quality of earnings, purchase price negotiation, and offering comprehensive partnership support to his clients. rn rn rn Emotional readiness and concessions are critical in M&A transactions.

Business 130
article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Cooley Outlook for 2018 M&A

Cooley M&A

280G Gross-Ups in Public Company Sales. Despite the “say on pay” environment and the elimination of virtually all 280G gross-ups in executive employment arrangements, we continue to see target boards approving full or partial 280G gross-ups for executives in connection with public company sales.

M&A 52
article thumbnail

Top 5 sectors attracting venture capital finance

Growth Business

In the last few years, new start-up and growth businesses have begun using AI to develop analytics platforms and planning tools to improve sales performance for smaller retailers. It also serves to professionalise the documentation and appearance of the company when engaging in contract negotiations with customers and suppliers.

Finance 52
article thumbnail

When Approval for a Drug “Indication” Gets Murky: Drafting Milestones to Avoid Disputes

Cooley M&A

The court agreed with Gilead, based primarily on a review of the parties’ drafting and negotiating history, which was corroborated by the parties’ contemporaneous statements made after the European Commission approved the deal. Throughout the trial, it was evident that the word had various meanings during the negotiations.

article thumbnail

Key Themes From Cooley’s M&A Dealmakers Roundtable: Insights on the Life Sciences M&A Market

Cooley M&A

The panel kicked off with a discussion about what types of assets pharmaceutical buyers tend to gravitate toward – both from a general market perspective and from the more specific view of Horizon. Key areas of interest for buyers and investors. rheumatology, nephrology, ophthalmology and endocrinology) and diseases within those areas.

M&A 40
article thumbnail

Monetizing an Earn-Out – Does That Make It a “Security?”

Cooley M&A

As with any security, the offering or sale must either be registered with the SEC or issued pursuant to a registration exemption, most typically in a private placement that is premised on issuances being made to mostly sophisticated, or “accredited,” investors (in reliance on the safe-harbor provisions of Regulation D under the Securities Act).